Novavax's updated vaccine has been granted emergency-use authorization by the
World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older, the company said on Tuesday.
The single-target vaccine is aimed at the XBB.1.5 Omicron subvariant of the coronavirus, which was dominant in the U.S. for much of this year but has since been overtaken by other variants as the virus evolves.
Novavax missed out on the
COVID-19 vaccine windfall, which benefited rivals, due to manufacturing issues that delayed its filing for approval during the peak of the pandemic.
The Maryland-based biotech's updated COVID shot, which was authorized in the U.S. in October, uses a more traditional protein-based technology than the mRNA-based vaccines by rivals Pfizer and Moderna.
